Shares of Novo Nordisk A/S (NYSE:NVO) gapped up before the market opened on Thursday . The stock had previously closed at $53.65, but opened at $53.82. Novo Nordisk A/S shares last traded at $54.12, with a volume of 754,739 shares.

A number of analysts have recently commented on NVO shares. Citigroup Inc. restated a “buy” rating on shares of Novo Nordisk A/S in a report on Friday, April 1st. Zacks Investment Research downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, May 2nd. Finally, Goldman Sachs Group Inc. downgraded Novo Nordisk A/S from a “conviction-buy” rating to a “buy” rating in a report on Tuesday, June 28th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $61.00.

The firm has a market capitalization of $137.57 billion and a PE ratio of 26.97. The firm has a 50 day moving average price of $54.16 and a 200 day moving average price of $54.44.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Friday, April 29th. The company reported $0.57 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.04. Equities analysts anticipate that Novo Nordisk A/S will post $2.30 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of NVO. Alta Capital Management LLC raised its position in Novo Nordisk A/S by 3.8% in the fourth quarter. Alta Capital Management LLC now owns 686,604 shares of the company’s stock worth $39,877,000 after buying an additional 25,425 shares in the last quarter. Bradley Foster & Sargent Inc. CT raised its position in Novo Nordisk A/S by 4.9% in the fourth quarter. Bradley Foster & Sargent Inc. CT now owns 35,421 shares of the company’s stock worth $2,057,000 after buying an additional 1,660 shares in the last quarter. WBI Investments Inc. purchased a new position in Novo Nordisk A/S during the fourth quarter worth approximately $27,205,000. Alpha Cubed Investments LLC raised its position in Novo Nordisk A/S by 8.9% in the fourth quarter. Alpha Cubed Investments LLC now owns 17,419 shares of the company’s stock worth $1,012,000 after buying an additional 1,424 shares in the last quarter. Finally, Emerson Investment Management LLC raised its position in Novo Nordisk A/S by 2.0% in the fourth quarter. Emerson Investment Management LLC now owns 89,245 shares of the company’s stock worth $5,183,000 after buying an additional 1,755 shares in the last quarter.

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.